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Abstract
Malignant melanoma is among the most aggressive cancers and its incidence is increasing worldwide. Targeted therapies
and immunotherapy have improved the survival of patients with metastatic melanoma in the last few years; however,
available treatments are still unsatisfactory. While the role of the BRAF-MEK1/2-ERK1/2 pathway in melanoma is well
established, the involvement of mitogen-activated protein kinases MEK5-ERK5 remains poorly explored. Here we
investigated the function of ERK5 signaling in melanoma. We show that ERK5 is consistently expressed in human
melanoma tissues and is active in melanoma cells. Genetic silencing and pharmacological inhibition of ERK5 pathway
drastically reduce the growth of melanoma cells and xenografts harboring wild-type (wt) or mutated BRAF (V600E). We
also found that oncogenic BRAF positively regulates expression, phosphorylation, and nuclear localization of ERK5.
Importantly, ERK5 kinase and transcriptional transactivator activities are enhanced by BRAF. Nevertheless, combined
pharmacological inhibition of BRAFV600E and MEK5 is required to decrease nuclear ERK5, that is critical for the
regulation of cell proliferation. Accordingly, combination of MEK5 or ERK5 inhibitors with BRAFV600E inhibitor
vemurafenib is more effective than single treatments in reducing colony formation and growth of BRAFV600E melanoma
cells and xenografts. Overall, these data support a key role of the ERK5 pathway for melanoma growth in vitro and in vivo
and suggest that targeting ERK5, alone or in combination with BRAF-MEK1/2 inhibitors, might represent a novel approach
for melanoma treatment.
Introduction
Malignant melanoma is one of the most aggressive types of
cancer. While early-stage melanoma can be cured in the
majority of cases by surgical excision, late-stage melanoma
is a highly lethal disease [1, 2]. Common genetic alterations
associated with melanoma include mutually exclusive
mutations in BRAF (50–60%), NRAS (20–25%), and NF1
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(14%) [3, 4]. These mutations drive the hyperactivation of
the mitogen-activated protein kinases (MAPK) extracellular
signal-regulated kinase 1 and 2 (ERK1/2) [5], which, in
turn, promotes tumor cell growth.
Over the last few years, new BRAF-targeting and
MEK1/2-targeting drugs as well as immunotherapy have
improved progression-free and overall survival of mela-
noma patients [6–8]. However, development of resistance in
Fig. 1 Expression of ERK5 in melanoma. a Genomic profiles of
components of the ERK5 pathway in melanoma patients obtained from
Skin Cutaneous Melanoma data set (TCGA, Provisional) using
cBioportal database (www.cbioportal.org) [28, 29]. Shown are 223 out
of 479 (47%) primary and metastatic melanomas with gene copy
number and mRNA alterations. Putative passenger mutations are not
included. MAPK7 and MAP2K5 are the genes encoding for ERK5/
BMK1 or MEK5, respectively. b Kaplan–Meier overall survival (OS)
and disease-free survival (DFS) in melanoma patients with (red) or
without (blue) ERK5 genetic alterations (data set from cBioportal
restricted to “AMP EXP >= 2” to exclude patients harboring MAPK7
deletion). Median months survival: 43.8 vs 85 (p= 4.79e−4, log-rank
test); median months disease free: 35 vs 51.5 (p= 0.042, log-rank
test). c Immunohistochemical analysis of ERK5 (top and middle
panels) and H&E (bottom panels) in human melanoma tissue array
cores. ERK5 was counterstained with hematoxylin. Samples were
scored as low, medium, or high ERK5 expression (see Supplementary
Table 1 for details and clinico-pathological characteristics of samples).
Top panels show representative cores at low magnification. Middle
and bottom panels are high magnification of top images. Bar= 40 μm.
d Quantification of ERK5 expression in primary and metastatic mel-
anomas from c. e Expression of ERK5 in melanoma cell lines. Cells
were serum starved for 24 h and total cell lysates were obtained.
GAPDH was used as a loading control. Arrow indicates ERK5 slow
migrating band. f In vitro kinase assay from immunoprecipitated
ERK5 in melanoma cell lines. IgG is a control sample without anti-
ERK5 antibody. MBP was used as a loading control. g Expression of
ERK5 in nuclear and cytoplasmic extracts in four melanoma cell lines.
Black lines indicate that samples were run on the same gel but were
noncontiguous. GAPDH and Fibrillarin were used as cytoplasmic or
nuclear markers, respectively. e–g Representative blots from three
independent experiments
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patients with oncogenic mutations remains a major obstacle
to the long-term clinical benefit of targeted therapies [9]. In
contrast, immunotherapy is the only effective treatment
option for patients who are wild type (wt) for BRAF,
NRAS, or NF1, albeit some of these patients fail to respond
to immunotherapy [10]. Thus, there is an urgent need to
identify druggable signaling pathways critical for melanoma
cell growth.
A further member of the MAPK family, ERK5 (also
referred to as big mitogen-activated Kinase 1, BMK1), is
involved in cell survival, anti-apoptotic signaling, angio-
genesis, differentiation and proliferation of several cell
types [11]. ERK5 possesses an N-terminal kinase domain
highly homologous to that of ERK1/2 and a unique long C-
terminal domain. Mitogens that activate receptor tyrosine
kinases [12], as well as cytokines and stress factors may
lead to the activation of MAP3K2 and MAP3K3, upstream
activators of MEK5, which in turn activates ERK5 through
phosphorylation on Thr218/Tyr220 in the catalytic domain
[11, 13]. Moreover, extensive phosphorylation of ERK5 at
the C terminus may occur during cell cycle progression in a
MEK5-independent manner [14, 15]. Phosphorylation at
MEK5 consensus site and/or at C terminus as well as other
mechanisms are involved in ERK5 nuclear translocation,
which is a key event for the regulation of cell proliferation
[16–19]. The MEK5-ERK5 pathway is involved in the
pathogenesis of different types of cancer, including highly
aggressive forms of breast [20, 21] and prostate cancer [22],
hepatocellular carcinoma [23] and multiple myeloma [24].
Thus, the MEK5-ERK5 pathway is becoming a promising
target for cancer treatment [25, 26]. Here we explored the
role of ERK5 pathway in melanoma and its regulation by
oncogenic BRAF.
Results
ERK5 is consistently expressed and active in human
melanoma
In silico data analysis of components of ERK5 signaling
indicated that the activators MAP3K2, MAP3K3 and
MAP2K5 (alternative name for MEK5), MAPK7 itself (the
gene encoding for ERK5), and the downstream targets
MEF2 transcription factors [27] (i.e., MEF2A, MEF2B,
MEF2C, and MEF2D) are altered (mutations, gene copy
number, or mRNA alterations) in 47% of human melano-
mas (Fig. 1a) [28, 29]. Interestingly, melanoma patients
with MAPK7 alterations (mRNA upregulation and MAPK7
amplifications but not deletions) showed reduced disease-
free survival (p= 0.042) and a trend toward shorter overall
survival (p= 4.793e−4) compared to patients without such
alterations (Fig. 1b). Immunohistochemical analysis of
ERK5 in tissue microarrays showed that ERK5 was
expressed in benign and malignant melanocytes, but not in
keratinocytes. ERK5 staining was observed in both cyto-
plasm and nucleus (Fig. 1c). As expected, endothelial cells
were positive for ERK5 [11] (Fig. 1c). ERK5 was expressed
at low, medium, or high levels in the majority of nevi (9 out
of 11; 82%) and of primary and metastatic melanomas (51
out of 66; 77%; Fig. 1d and Supplementary Table 1).
Accordingly, ERK5 was expressed in a number of com-
mercial and patient-derived melanoma cell lines and normal
human epidermal melanocytes (NHEM; Supplementary
Table 2; Fig. 1e and Supplementary Figure 1a) [30].
Moreover, in most of the cell lines analyzed (SK-Mel-5,
SK-Mel-2, MeWo, SSM2c, and M26c) ERK5 presented a
slower migrating band, consistent with the phosphorylation
(Fig. 1e). As expected, marked ERK1/2 phosphorylation
was found in melanoma cells with mutations in BRAF,
NRAS, or NF1 (Fig. 1e and Supplementary Table 2). For
subsequent experiments, we used two melanoma cell lines
expressing wt (SSM2c and M26c) and two harboring
mutated (V600E) BRAF (A375 and SK-Mel-5). Kinase
assay from immunoprecipitated ERK5 showed that ERK5 is
constitutively active in all four cell lines, as shown by
phosphorylation of the myelin basic protein (MBP) with
respect to the IgG control (Fig. 1f).
ERK5 nuclear translocation is a key event for ERK5
activity [19]. Therefore, we evaluated ERK5 intracellular
localization and found that ERK5 was located in both the
cytoplasm and the nucleus in all four melanoma cell lines
(Fig. 1g). Altogether, these data indicate that the ERK5
pathway is consistently expressed and is active in human
melanoma.
ERK5 is required for melanoma cell proliferation
in vitro and xenograft growth
ERK5 plays a relevant role in the growth of several types of
cancer [20–26]. Thus, we investigated the effects of the
inhibition of ERK5 signaling in melanoma cell prolifera-
tion. Genetic inhibition of ERK5 [23] using two specific
shRNAs (LV-shERK5-1 and LV-shERK5-2) markedly
reduced the growth of melanoma cells harboring wt or
mutated (V600E) BRAF (Fig. 2a–c). To investigate whether
ERK5 regulates melanoma growth in vivo, A375 and
SSM2c melanoma cells stably transduced with LV-c or LV-
shERK5-1 were subcutaneously injected into athymic nude
mice and tumor growth was monitored. ERK5 silencing
drastically reduced A375 xenograft growth and diminished
by 70% that of SSM2c xenografts compared to LV-c (Fig.
2d–g). Silencing of ERK5 reduced, but did not abolish,
tumor take and delayed tumor appearance in both cell types
(Fig. 2h). Western blot analysis in tumors dissected at the
end of experiments confirmed the drastic reduction of
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ERK5 in LV-shERK5-transduced cells (Fig. 2i). Altogether,
these results indicate that ERK5 plays a critical role in
melanoma cell growth in vitro and in vivo.
Pharmacological inhibition of the ERK5 pathway
decreases melanoma cell growth
In view of a possible translation to the clinics, we deter-
mined the effects of pharmacological inhibition of the
ERK5 pathway using the ERK5 inhibitor XMD8-92 [31] or
the MEK5 inhibitor BIX02189 [32]. Either drug abolished
the slower migrating band of ERK5, proving reduced ERK5
phosphorylation likely as a consequence of reduced
autophosphorylation (XMD8-92) or decreased interaction
with and phosphorylation by MEK5 (BIX02189) (Supple-
mentary Figure 1b). XMD8-92 or BIX02189 treatment
decreased the number of viable cells in a dose-dependent
manner in several melanoma cell lines expressing either wt
or BRAFV600E (Fig. 3a–c), with IC50 values ranging from
2.3 to 3.7 μM for XMD8-92, and from 5.4 to 7.1 μM for
BIX02189. Moreover, because XMD8-92 has been reported
to be a dual ERK5/BRD4 inhibitor [33], we confirmed the
effects on cell proliferation with JWG0-45 (Supplementary
Figure 2a), a novel ERK5 inhibitor with much lower affinity
Fig. 2 Silencing of ERK5
inhibits melanoma cell
proliferation in vitro and in
human melanoma xenografts. a,
b Growth curves of A375 (a)
and SSM2c (b) cells transduced
with LV-shERK5 or LV-c
lentiviruses. Data shown are
mean ± SD of one representative
experiment out of three
performed in triplicates. **p <
0.01 as determined by Student's
t-test. c Western blot shows
ERK5 silencing efficiency
(upper panel). Tubulin was used
as loading control. Images of
one representative experiment
out of three performed with
A375 cells transduced with the
indicated lentiviruses stained
with crystal violet after 10 days
(lower panel). d, e In vivo tumor
growth after subcutaneous
injection of 1 × 104 A375 (d) or
SSM2c (e) melanoma cells
transduced with LV-c or LV-
shERK5-1 lentiviruses. Data
shown are mean ± SEM. *p <
0.05, **p < 0.01 and ***p <
0.001 as determined by Student's
t-test. f, g Representative images
of A375 and SSM2c xenografts
in athymic nude mice. Bar=
10 mm. h Table shows tumor
take (number of tumors formed
per number of injections) and
latency (time from injection to
tumor measurability) for each
group. Data shown are mean ±
SEM. i Western blot analysis of
representative tumors derived
from A375 and SSM2c
xenografts. Actin was used as
loading control
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toward BRD proteins [34]. Furthermore, no reduction in
cell proliferation was observed when XMD8-92 (up to 5
µM, which is the concentration used throughout the
manuscript) was applied to ERK5-silenced melanoma cells
(Supplementary Figure 2b and c). These results seem to
exclude that the effect of XMD8-92 on cell proliferation, at
least at the concentration used in these cells, are due to off-
target effects.
In order to analyze how inhibition of the ERK5 pathway
affects cell growth, we performed cell cycle analysis. In
BRAFV600E-expressing cells (A375 and SK-Mel-5),
treatment with either XMD8-92 or BIX02189 markedly
increased the fraction of cells in G0/G1 phase, mainly at the
expenses of those in S phase. In addition, treatment with
BIX02189 significantly reduced the number of cells in G2/
M phase (Fig. 3d, e). Consistently, BIX02189 and, to a
lesser extent, XMD8-92 reduced the level of pRb (Ser807)
in BRAFV600E-expressing cells (Fig. 3h). Treatment with
XMD8-92 increased the expression of the cyclin-dependent
kinase inhibitor (CDKi) p21. Finally, treatment with
BIX02189 and, to a lesser extent, XMD8-92 decreased the
expression of cyclin D1 and B1 (Fig. 3h).
In wt BRAF melanoma cells (SSM2c and M26c),
XMD8-92 treatment resulted in a marked accumulation in
G2/M phase at the expense of those in G0/G1 and S phases
(Fig. 3f, g) and increased p21 expression. JWG-045 pro-
duced similar effect on cell cycle phase distribution (Sup-
plementary Figure 2d). On the other hand,
Fig. 3 Pharmacological inhibition of the ERK5 pathway reduces
melanoma cell proliferation in vitro. a, b Dose-response curves of
XMD8-92 (a) and BIX02189 (b) in a number of melanoma cell lines
after 72 h of treatment or DMSO (CTR). Data shown are mean ± SD
from four independent experiments performed in triplicates. c IC50
values for XMD8-92, BIX02189 and vemurafenib in melanoma cells
treated for 72 h. d–g Cell cycle phase distribution plots and values
(tables) of BRAFV600E-expressing cells (A375 and SK-Mel-5) (d, e)
and of wt BRAF cells (SSM2c and M26c) (f, g). Cells were treated for
48 h with XMD8-92 (5 μM) or BIX02189 (10 μM). Data shown are
mean ± SD from four independent experiments. *p < 0.05, **p < 0.01
as determined by Student's t-test. h Expression or phosphorylation
status of cell cycle regulators in cells treated for 24 h with XMD8-92
(5 μM) or BIX02189 (10 μM). *p < 0.05, **p < 0.01 as determined by
Student's t-test. Total cell lysates were obtained. Vinculin was used as
loading control. Densitometric analysis was performed on three
independent experiments. Controls were treated with DMSO
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BIX02189 slightly affected cell cycle distribution, with a
trend toward an increase in the number of cells in S phase
and a reduction of those in G2/M phase (Fig. 3f, g).
Accordingly, no major differences were found in the
phosphorylation of Rb nor in the expression of Cyclin B1
and D1 following XMD8-92 or BIX02189 treatment. The
reduction of cell number observed in melanoma cells treated
with BIX02189 may be due to an increase of apoptosis
(Supplementary Figure 3). These results demonstrated that
pharmacological inhibition of the MEK5-ERK5 signaling
in vitro mimics the effects of ERK5 genetic inhibition in
reducing melanoma cell proliferation.
Oncogenic BRAF increases ERK5 activity
ERK5 is expressed and active in melanoma cells (Fig. 1).
Because BRAF is mutated in ~50% of melanomas, we
investigated whether BRAF modulates ERK5 activation. To
address this point, we overexpressed oncogenic BRAF in
HEK-293T and melanoma cells expressing wt BRAF. In
both cell types, BRAFV600E increased endogenous and
exogenous ERK5 protein levels (Supplementary Figure 4
and Fig. 4a). Oncogenic BRAF induced a robust phos-
phorylation of ERK5 at Ser753 and at Thr732 (Fig. 4a), two
residues in the ERK5 C-terminal region that are putative
Fig. 4 Oncogenic BRAF enhances ERK5 expression and activation. a
M26c melanoma cells and HEK-293T cells were transfected with
equimolar amounts of pcDNA (control, −) or wt ERK5 in combina-
tion with pcDNA, constitutively active MEK5 (MEK5DD), wt BRAF,
or BRAFV600E plasmids. Cells were lysed after 48 h and western blot
was performed with the indicated antibodies. HSP90 was used as a
loading control. b HEK-293T cells were transfected with equimolar
amounts of pcDNA (control) or wt ERK5 in combination with pcDNA
or BRAFV600E plasmids. Cells were treated with the ERK1/2 inhi-
bitor SCH772984 (0.5 µM) and/or the CDK1 inhibitor RO-3306 (9
μM) during the last 18 h of transfection. Cells were lysed after 24 h and
western blot was performed with the indicated antibodies. HSP90 was
used as a loading control. c In vitro kinase assay for ERK5 immu-
noprecipitated from M26c cells transfected with equimolar amounts of
pCAG, constitutively active MEK5 (MEK5DD) or BRAFV600E
plasmids. MBP was used as a loading control. d In vitro kinase assay
for ERK5 immunoprecipitated from A375 or SK-Mel-5 cells treated
with 1 µM vemurafenib (Vem) or DMSO (Control) for 24 h. MBP was
used as a loading control. Blots are representative images from five (a)
or three (b) independent experiments. c–d Relative ERK5 kinase
activity determined by densitometric quantification of pMBP nor-
malized for MBP from three independent experiments (mean ± SD).
pCAG and DMSO controls were set to 1. *p < 0.05 as determined by
Student's t-test
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autophosphorylation sites as well as targets of CDK1 and/or
ERK1/2 (see below) [15, 35]. Ectopic expression of con-
stitutively active MEK5 (MEK5DD) induced robust ERK5
phosphorylation at Thr218/Tyr220, as expected, and
increased ERK5 phosphorylation at Thr732 (Fig. 4a).
Overexpression of oncogenic BRAF induced ERK5 phos-
phorylation at Thr218/Tyr220, although to a lower level
than that induced by MEK5DD (Fig. 4a). Ectopic expres-
sion of wt BRAF elicited similar effects on the expression
and phosphorylation of ERK5, although to a lesser extent.
These results indicate that overexpression of BRAF, either
wt or mutated (V600E), determines an increase of ERK5
protein level and phosphorylation at different residues.
To assess whether phosphorylation of ERK5 at the C
terminus is critical for the regulation of ERK5 expression
levels by BRAF, we used a mutated form of ERK5
(ERK5Δ713) lacking the C terminus. BRAFV600E was
able to enhance the expression level of ERK5Δ713 at the
same level of full-length ERK5, possibly due to higher
phosphorylation at Thr218/Tyr220 with respect to wt ERK5
(Supplementary Figure 5). Nevertheless, BRAFV600E
increased the level of expression of ERK5-AEF (a mutated
form of ERK5 that cannot be phosphorylated at Thr218/
Tyr220), indicating that the regulation of ERK5 expression
level by BRAFV600E likely depends on phosphorylation at
any of the aforementioned residues. This is well in keeping
with the fact that phosphorylation at different residues has
been reported to sustain ERK5 protein levels [18].
Because Ser753 can be also phosphorylated by CDK1
(ref. 15), whereas Thr732 is phosphorylated by both CDK1
and ERK1/2 (ref. 35), we investigated the involvement of
these two kinases in BRAFV600E-dependent regulation of
ERK5. Treatment with the ERK1/2 inhibitor SCH772984 or
the CDK1 inhibitor RO-3306 reduced ERK5 protein level
and phosphorylation at Ser753 and Thr732, and their
combination completely abolished BRAFV600E-induced
effects (Fig. 4b). The efficacy of SCH772984 on ERK1/2
and of RO-3306 on CDK1 was demonstrated, respectively,
by decreased phosphorylation of ERK1/2 and increase of
Cyclin B, as previously reported [15]. These data indicate
that CDK1 and ERK1/2 contribute to BRAF-dependent
regulation of ERK5 phosphorylation and protein amount.
We next investigated whether oncogenic BRAF affects
ERK5 activity. Overexpression of BRAFV600E enhanced
ERK5 kinase activity (Fig. 4c). Consistently, pharmacolo-
gical inhibition of BRAFV600E with vemurafenib mark-
edly reduced basal ERK5 kinase activity in A375 and SK-
Mel-5 cells (Fig. 4d). To exert its proliferative activity,
ERK5 translocates into the nucleus [19]. Overexpression of
BRAFV600E increased the nuclear amount of total and
phosphorylated (at Ser753 and Thr732) ERK5 (Fig. 5a).
More importantly, oncogenic BRAF increased the amount
Fig. 5 Oncogenic BRAF increases ERK5 nuclear localization and
transcriptional transactivator activity. a Nucleo-cytoplasmic fractio-
nation in HEK-293T cells transfected with equimolar amounts of wt
ERK5 in combination with the empty vector pCAG, constitutively
active MEK5 (MEK5DD) or BRAFV600E plasmids. BRAFV600E
increases the level and the phosphorylation of nuclear ERK5. GAPDH
and Lamin B1 were used as cytoplasmic or nuclear markers, respec-
tively. b Nucleoplasm and chromatin-bound fraction from HEK-293T
cells transfected with equimolar amounts of empty or BRAFV600E
pcDNA plasmids in presence or not of wt ERK5. Rb and Histone H4
were used as nucleoplasm or chromatin-bound markers, respectively.
(a, b) Representative blots from three independent experiments. c
Quantification of dual reporter luciferase assay in M26c melanoma
cells showing that BRAFV600E enhances the transcriptional transac-
tivator activity of wt ERK5. Relative luciferase activity was firefly/
Renilla ratios, with the level induced by control equated to 1. Data
represent mean ± SD of three independent experiments. **p < 0.01,
***p < 0.001 as determined using one-way ANOVA
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Fig. 6 Combined pharmacological inhibition of the ERK5 pathway
and BRAFV600E reduces melanoma cell growth in vitro and in vivo.
a Cytoplasmic and nuclear extracts of A375 or SK-Mel-5 melanoma
cells showing the effect of vemurafenib (1 μM), BIX02189 (10 μM) or
the combination on the expression of endogenous ERK5. GAPDH and
Lamin A were used as cytoplasmic or nuclear markers, respectively.
Quantification of cytoplasmic and nuclear endogenous ERK5 nor-
malized for loading control from three independent experiments is
shown in histograms (mean ± SD). *p < 0.05 as determined by Stu-
dent's t-test. b, c 2D colony forming assay in A375 (b) and SK-Mel-5
(c) cells treated with DMSO (Control) or IC50 concentration of
XMD8-92 (A375: 2.5 μM; SK-Mel-5: 2.0 μM), BIX02189 (A375: 2.5
μM; SK-Mel-5: 5.5 μM) or vemurafenib (A375: 0.5 μM; SK-Mel-5:
0.45 μM) alone or in combination. Histograms represent mean ± SD
from four independent experiments. **p < 0.01 treatment vs Control;
##p < 0.01 between indicated samples. P values were determined using
one-way ANOVA. Below are representative images of plates (left) or
colonies (right). d, e Number of viable A375 (d) and SK-Mel-5 (e)
cells treated for 72 h with DMSO (Control), vemurafenib, XMD8-92,
or the combination (Vem+XMD) at the indicated concentrations.
Histograms represent mean ± SD from one representative experiment
out of three performed in triplicate. Bliss independence indicates
additive effects in Vem+XMD vs Vem or XMD. *p < 0.05, **p <
0.01, ***p < 0.001 as determined by one-way ANOVA. f In vivo
tumor growth of A375 melanoma cells subcutaneously injected (1 ×
104). Mice were treated at tumor appearance with vemurafenib (20 mg/
kg), XMD8-92 (25 mg/kg) or the combination. After 19 days of
treatment mice were sacrificed. Data shown are mean ± SEM. Com-
bined treatment increased the efficacy of XMD8-92 or vemurafenib
alone. Number of tumors for each group is indicated. *p ≤ 0.05; **p <
0.01 as determined by one-way ANOVA. g Representative images of
A375 xenografts in athymic nude mice. Bar= 10 mm
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of ERK5 in the chromatin-bound fraction (Fig. 5b) and
enhanced the ability of ERK5 to induce transcription using
a MEF2 luciferase reporter (Fig. 5c). Altogether, these data
indicate that oncogenic BRAF positively regulates ERK5
activity.
The combination of vemurafenib with ERK5
pathway inhibitors provides enhanced inhibition of
melanoma cell growth compared to single
treatments
The data above demonstrate that BRAF is an upstream
activator of ERK5. However, a 24-hour treatment with
vemurafenib did not decrease nuclear ERK5 (Fig. 6a), likely
due to the occurrence of MEK5-dependent phosphorylation
of ERK5 upon MEK1/2 inhibition, as recently reported
[36]. In keeping with that, combined treatment with
vemurafenib and BIX02189 was needed to reduce the
amount of nuclear ERK5 in A375 and SK-Mel-5 melanoma
cells (Fig. 6a). Similar effects, i.e., reduction of active
nuclear ERK5, were elicited by combination of vemur-
afenib and XMD8-92 (Supplementary Figure 6). To test
whether targeting both the MEK5-ERK5 and BRAF path-
way leads to a better response than single treatments, we
performed 2D colony formation assays using vemurafenib
in combination with XMD8-92 or BIX02189 at IC50 con-
centrations (Supplementary Figure 7). Either drug combi-
nation was more effective than single treatments, preventing
colony formation completely (Fig. 6b, c). Likewise, the
combination of vemurafenib with XMD8-92 displayed
additive effects in reducing proliferation of A375 and SK-
Mel-5 grown in monolayer (Fig. 6d, e). Taken together,
these data suggest that vemurafenib and ERK5 pathway
inhibitors cooperate in reducing melanoma cell growth.
To examine the efficacy of vemurafenib and XMD8-92
combination in vivo, we assessed the effects of single drugs
or their combination in a pre-clinical experimental setting
based on BRAFV600E-expressing A375 xenografts.
Treatments started when tumors were palpable. Single
treatment with low doses of vemurafenib (20 mg/kg) [37,
38] or XMD8-92 (25 mg/kg) [21] twice a day for 19 days
produced a 50% tumor growth inhibition compared to the
control group (Fig. 6f, g). Combination treatment with
vemurafenib (20 mg/kg) and XMD8-92 (25 mg/kg)
achieved a significantly greater antitumor effect than either
agent alone (Combo vs Vem p= 0.05; Combo vs XMD8-
92 p= 0.005), paralleling results obtained in vitro. Treat-
ment with single agents or their combination was generally
well tolerated, without significant weight loss or other overt
side effects. Altogether, these results demonstrate that
inhibition of the ERK5 pathway improves the effect of
vemurafenib treatment against melanoma growth in vitro
and in vivo.
Discussion
In this study, we demonstrate the requirement of the ERK5
pathway for melanoma growth. Indeed, genetic silencing of
ERK5 or pharmacological inhibition of ERK5 signaling
with two chemically unrelated small molecules dramatically
reduce the proliferation of melanoma cells harboring wt or
oncogenic BRAF. Importantly, combination of vemurafenib
and ERK5 pathway inhibitors, used at doses able to reduce
cell proliferation by half, suppresses 2D colony formation
and is more effective than single treatments in reducing
growth of BRAFV600E melanoma xenografts. Mechan-
istically, we show that oncogenic BRAF positively reg-
ulates the expression, phosphorylation and nuclear
localization of ERK5 as well as its kinase and transcrip-
tional transactivator activities.
Our immunohistochemical analysis shows that ERK5 is
expressed at different levels in the majority of human
melanomas. In addition, in silico data analysis indicates that
47% of melanoma patients have alterations in components
of the ERK5 pathway. These alterations mainly consist of
increased mRNA or gene amplification that are likely
responsible for enhanced activation of the pathway. Inter-
estingly, melanoma patients with increased mRNA or
amplification of MAPK7, the gene encoding for ERK5,
have a shorter disease-free survival compared to patients
without such alterations. We also found that 5 out of 479
melanoma patients harbor MAPK7 missense mutations,
including P789S and A424S, two potentially phosphoryl-
able sites worth being characterized in future studies.
Overall, these data identify a wide subgroup of melanoma
patients that might benefit from targeting the ERK5
pathway.
Our data indicate that pharmacological inhibition of the
ERK5 pathway strongly reduces melanoma cell growth. In
BRAFV600E-expressing cells, MEK5 or ERK5 inhibitors
slow down cell cycle progression with the accumulation of
cells in G0/G1 phase, likely due to a decreased phosphor-
ylation of Rb, a key regulator of the G1 to S phase transi-
tion, as previously described [39]. Furthermore,
pharmacological inhibition of MEK5 or ERK5 reduces
cyclin D1 levels and increases p21 expression as reported in
other cell types [39]. In melanoma cells expressing wt
BRAF, pharmacological inhibition of ERK5 signaling
reduces melanoma cell growth, increasing apoptosis
(BIX02189) or blocking cell cycle progression (XMD8-92).
Therefore, both BIX02189 and XMD8-92 reduce mela-
noma cell growth. More importantly, genetic silencing of
ERK5 recapitulates, in vitro and in vivo, the effects of
pharmacological inhibition of the ERK5 pathway, pointing
to the requirement of ERK5 for proliferation of melanoma
cells with either wt or BRAFV600E.
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An intriguing point emerging from our data is that the
involvement of ERK5 in cancer cell proliferation sustained
by oncogenic BRAF or RAS is context dependent. Indeed,
we show here that ERK5 is required for BRAFV600E-
driven proliferation in melanoma in vitro and in vivo. In
addition, we previously reported that hepatocellular carci-
noma cells, including HepG2 that harbor mutated NRAS
(Q61L) [40], are sensitive to genetic and pharmacological
inhibition of ERK5 in vitro and in vivo [23]. In contrast,
colon cancer cells with KRAS or BRAF mutations do not
appear to be addicted to ERK5 activity for proliferation at
least in vitro [41].
Another important finding of this study is the identifi-
cation of a new mechanism of ERK5 regulation (Fig. 7).
Our data indicate that oncogenic BRAF increases ERK5
protein level, phosphorylation at several residues and kinase
activity. More importantly, BRAFV600E enhances ERK5
nuclear localization, including that in the chromatin-bound
fraction, and transcriptional transactivator activity. This is at
variance with a previous report showing that BRAFV600E
does not enhance ERK5-driven transcriptional activity in
presence of overexpressed wt MEK5 in HEK-293T cells
[41]. A possible explanation for this discrepancy could be
that MEK5 by itself induces an increase of MEF2D-
mediated luciferase activity [42], masking the effect of
oncogenic BRAF. Alternatively, the effect could be context
dependent since our experiments were performed in mela-
noma cells.
In addition, we show that oncogenic BRAF promotes
ERK5 phosphorylation at three crucial sites. First, BRAF
increases phosphorylation at Thr732, an event that has been
associated with increased ERK5 nuclear localization and
ERK5-dependent transcription [35]. Phosphorylation at this
residue is prevented by pharmacological inhibition of
ERK1/2 and CDK1, pointing to their possible involvement.
Second, BRAF enhances ERK5 phosphorylation at Ser753,
an additional CDK1 target residue. However, the fact that
pharmacological inhibition of CDK1 does not completely
abolish phosphorylation at this site leaves open the possi-
bility that Ser753 is either autophosphorylated, as is the case
for other residues at C terminus of ERK5 [35, 42], or is the
substrate of a yet unidentified kinase. The effect of the
ERK1/2 inhibitor SCH772984 in abrogating phosphoryla-
tion at Ser753 may indicate that ERK1/2 acts upstream of
CDK1, which is consistent with the presence of active
CDK1 in oncogenic BRAF-overexpressing cells (Supple-
mentary Figure 5). Finally, overexpression of BRAF indu-
ces ERK5 phosphorylation at Thr218/Tyr220, suggesting
that MEK5 participates in BRAF-induced ERK5 activation
(Fig. 7). Increased ERK5 phosphorylation at Thr218/
Tyr220 by oncogenic BRAF has been showed in a previous
report, although the authors reached different conclusions
stating that oncogenic BRAF does not stimulate ERK5
phosphorylation [41]. Together, these data indicate that
oncogenic BRAF, via CDK1, ERK1/2 and/or MEK5,
transduces mitogenic signals to the nucleus through ERK5
(Fig. 7). It has been recently reported that dietary-fat-fueled
ketogenesis promotes BRAFV600E melanoma growth [43].
On that basis, it would be interesting to investigate the role
of ERK5 in the effect exerted by high fat metabolism on
melanoma growth.
Our data indicate that vemurafenib inhibits ERK5 kinase
activity, but is not able to reduce the level of nuclear ERK5.
The reduction of total and/or active ERK5 is achieved only
by vemurafenib together with BIX02189 or XMD8-92, thus
providing the rationale for a combined treatment. Indeed,
combination of IC50 doses of XMD8-92 and vemurafenib
abolished two-dimensional colony formation and drastically
reduced melanoma xenograft growth. The experiments
presented here suggest that the combination of ERK5
pathway inhibitors with vemurafenib could be a good
strategy for the treatment of BRAF-mutant melanoma
patients. The combination therapy we propose could be also
important to prevent the recently reported ERK5-mediated
resistance to vemurafenib-trametinib treatment in melanoma
[44]. Further advocating combination therapy targeting
MEK1/2-ERK1/2 and ERK5 pathway, a recent report sug-
gested that pharmacological inhibition of ERK1/2 may
Fig. 7 Proposed mechanism for oncogenic BRAF-dependent ERK5
activation. Oncogenic BRAF may enhance ERK5 phosphorylation and
activity through: (i) CDK1 by phosphorylating ERK5 at Ser753 and/or
Thr732; (ii) a MEK1/2-ERK1/2-dependent mechanism (Thr732); (iii)
a MEK5-dependent mechanism (Thr218/Tyr220). Solid lines indicate
direct established regulatory interactions, whereas broken lines illus-
trate putative interactions. RO-3306 and SCH772984 are, respectively,
CDK1 and ERK1/2 inhibitors, XMD8-92 and JWG-045 are ERK5
inhibitors, BIX02189 is a MEK5 inhibitor
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induce ERK5 phosphorylation at MEK5 consensus sites in
colon cancer cells [36].
Overall this study suggests that targeting ERK5 might be
regarded as first-line therapeutic approach for melanoma
patients with wt or oncogenic BRAF, or as a potential
therapeutic strategy aimed at preventing resistance to
BRAF-MEK1/2 inhibitors. Because the immune system
plays a critical role in the progression of melanoma [8], a
potential caveat is that systemic inhibition of ERK5 might
impact on the immune system functions with respect to
tumor progression. Indeed, ERK5 has been reported to
either inhibit or stimulate T cell-mediated antitumor
immunity [45, 46] and to be critical for macrophage pro-
liferation [12]. Therefore, in view of a future use of ERK5
pathway inhibitors in human melanoma, the effects of
systemic ERK5 inhibition on immune response should be
further investigated.
Material and methods
Cell lines and melanoma samples
A375 (CRL-1619), MeWo (HTB-65), and HEK-293T
(CRL-3216) cells were obtained from ATCC (Manassas,
VA, www.lgcstandards-atcc.org). SK-Mel-2, SK-Mel-5,
SK-Mel-28, and 501-Mel melanoma cells were kindly
provided by Dr. Laura Poliseno (CRL-ITT, Pisa, Italy).
Patient-derived SSM2c and M26c melanoma cells were
already described [30] (Supplementary Table 2) and were
obtained from human melanoma samples after approved
protocols by the Ethics Committee. Cell lines were
authenticated by cell profiling (Promega PowerPlex Fusion
System kit; BMR Genomics s.r.l; Padova, Italy) once a
year. Mycoplasma was periodically tested by 4’,6-diami-
dino-2-phenylindole (DAPI) inspection and PCR upon
thawing of a new batch of cells and once a month. Cultures
are renewed every 2 months.
Drugs
The following drugs were used: ERK5 inhibitors XMD8-92
[31] and JWG-045 [34] have been developed in Gray’s
laboratory; MEK5 inhibitor BIX02189 [32], ERK1/2 inhi-
bitor SCH772984 [47] and BRAFV600E inhibitor vemur-
afenib [48] (Selleckchem, Italy, www.selleckchem.com);
CDK1 inhibitor RO-3306 (MedChem Express, www.
medchemexpress.com) [49].
RNA interference
Lentiviruses were produced in HEK-293T cells as pre-
viously reported [23]. Lentiviral vectors for stable
knockdown of ERK5 in melanoma cells were TRC1.5-
pLKO.1-puro vector containing non targeting sequence
shRNA (LV-c), targeting human MAPK7 (NM_139032,
NM_139034, NM_002749, NM_139033) clone ID:
TRCN0000010275 (LV-shERK5-1) as described [23] and
clone ID:TRCN0000010271 (5′-CCGGCCAGTCCAACC-
TACCAGTCCTCTCGAGAGGACTGGTAGGTTGGAC-
TGGTTTTT-3′; LV-shERK5-2). Transduced cells were
selected with 2 µg/ml puromycin for at least 72 h.
Measurement of cell viability and cell cycle phase
distribution
The number of viable cells in culture was evaluated by
counting trypan blue-negative cells at the indicated time-
points with an hemocytometer. IC50 values were calculated
using GraphPad Prism software. Cell cycle phase distribu-
tion (propidium iodide staining) was estimated by flow
cytometry using a FACSCanto (Beckton & Dickinson, San
Josè, CA, USA) as previously reported [23].
2D clonogenic assay
For colony formation assay, 500 (A375) or 3500 (SK-MEL-
5) cells were seeded in p60 dishes in the presence of drugs
or vehicle (DMSO). Colonies (with more than 50 cells, i.e.,
8 cell diameter) were counted following crystal violet
staining after 7 (A375) or 14 (SK-MEL-5) days [50]. IC50
values were calculated using GraphPad Prism software.
Cell lysis and Western blotting
Cells were lysed as already described in Laemmli [12] or
RIPA buffer [30]. Nucleo-cytoplasm fractions have been
obtained as previously described [23]. In other experiments,
subcellular fractionation was performed using the sub-
cellular protein fractionation kit (Pierce, Thermo Fisher
Scientific, Waltham, MA, USA) according to manu-
facturer’s instructions. Proteins were separated by
SDS–PAGE and transferred into PVDF or nitrocellulose
membranes (Millipore, www.merckmillipore.com) by
electroblotting. Infrared imaging (Odyssey, Licor, www.
licor.com) or chemiluminescent detection were performed.
Images were recorded as TIFF files for quantification with
Adobe Photoshop software. Antibodies used are listed in
Supplementary Table 3.
ERK5 kinase assay
Kinase activity of endogenous ERK5 was measured using a
non-radioactive ERK Assay Kit (#17-191, Merck Millipore,
Billerica, MA, USA) following manufacturer’s instruction.
The ability of immunoprecipitated ERK5 to phosphorylate
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myelin basic protein (MBP) was evaluated by western
blotting.
Luciferase assay
Luciferase reporter (3XMEF2-luc plasmid # 32967 was a
gift from Ron Prywes, Addgene, Teddington, UK) was used
in combination with Renilla luciferase pRL-TK reporter
vector (Promega, Madison, WI) to normalize luciferase
activities; pcDNA vector was used to equal DNA amounts.
Luminescence was measured using the Dual-Glo Luciferase
Assay System (Promega) and the GloMax® 20/20 Lumin-
ometer (Promega).
Xenografts
In the first set of experiments, A375 and SSM2c melanoma
cells transduced with LV-c or LV-shERK5 were resus-
pended in Matrigel (Corning, www.corning.com)/DMEM
(1/1) and subcutaneously injected (10,000 cells/injection)
into lateral flanks of adult (8 weeks) female athymic nude
mice (Foxn1 nu/nu) (Harlan Laboratories, Udine, Italy).
Number of animals (sample size) per group, calculated on
the basis of http://www.biomath.info/power/ttest.htm (two
groups > t-test on group means > find sample size), was 6
for A375 and SSM2c LV-shERK5 and 7 for SSM2c LV-c.
In the second set of experiments, parental A375 cells
were subcutaneously injected as above. Once tumors were
palpable (4 mm3), blind randomization of mice in four
groups of nine mice each was performed on the basis of size
and presence/absence of palpable tumors on each flank.
Mice were treated intraperitoneally twice a day for 19 days
with vehicle (30% 2-hydroxypropyl-β-cyclodextrin),
XMD8-92 (25 mg/kg), vemurafenib (20 mg/kg), or a com-
bination of both drugs. In both experiments subcutaneous
tumor size was measured three times a week with a caliper.
Tumor volumes were calculated using the formula: V=
W2 × L × 0.5, where W and L are tumor width and length,
respectively. On the basis of pre-established criteria, tumors
that had not developed at the time of randomization were
excluded from the analysis.
The experiments were approved by the Italian Ministry
of Health (authorization no. 213/2015-PR) and were in
accordance with the Italian guidelines and regulations.
Plasmids and transfection
pcDNA3.1-BRAFV600E and pcDNA3.1-BRAFwt con-
structs were a kind gift from Laura Poliseno (CRL-ITT,
Pisa, Italy). pcDNA3.1-HA-ERK5wt construct was a kind
gift from Atanasio Pandiella (CIC, Salamanca, Spain). The
pcMV5-MEK5DD-HA (a constitutively active form of
MEK5) was generously provided by Jiing-Dwan Lee
(Scripps Institute, La Jolla, CA, USA). HEK-293T or M26c
cells were plated on six-well dishes (3 × 105 cells/well) and
transfected after 24 h with a total amount of 3 μg of plasmid
DNA using Lipofectamin2000 (Invitrogen, Thermo Fisher
Scientific), following manufacturer’s instructions. Cells
were lysed after 24–48 h. Drugs were added 18 h before
lysis.
Immunohistochemistry
Immunohistochemistry was performed on tissue micro-
arrays (US Biomax, Inc., http://www.biomax.us) of
formalin-fixed paraffin-embedded specimens of human nevi
and melanomas. After citrate buffer antigen retrieval,
staining was performed with the UltraVision LP Detection
System HRP Polymer kit (#TL-015-HD, Thermo Fisher
Scientific) following manufacturer’s instructions. Sections
were incubated overnight at 4 °C with mouse monoclonal
anti-ERK5 (C-7) (sc-398015, 1:100 dilution) (S. Cruz, CA,
USA). DAB (3,3’-diaminobenzidine) (Thermo Fisher Sci-
entific) or AEC (3-amino-9-ethylcarbazole)(#K3461, Dako,
Copenhagen, Denmark) were used as chromogens. Sections
stained with AEC were counterstained with hematoxylin.
Statistical analysis
Data represent mean ± SEM or mean ± SD values calculated
on at least three independent experiments. The exact num-
ber of experiments performed and used for statistical ana-
lysis is indicated in each figure legend. No statistical
methods were used for sample size selection. Variance
between groups that have been statistically compared was
similar. P values were calculated using Student's t-test (two
groups) or one-way analysis of variance (more than two
groups; multiple comparison using Bonferroni’s correction).
Analysis of in vivo combined treatments were performed
using the false discovery rate adjustment for multiple
comparisons. A two-tailed value of p < 0.05 was considered
statistically significant. Number of mice used for each
experiment were indicated above.
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